---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-038044"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T05:58:43.815633+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Assembly Bio reports FY 2023 net loss of $61.2M; cash of $130.2M; outlines 2024 milestones

## Summary
- Cash, equivalents and marketable securities $130.2M as of Dec 31, 2023, up from $91.6M at end of 2022; funded into H2 2025.
- Revenue from collaborations $7.2M in FY 2023 (vs $0 in 2022), primarily from Gilead partnership.
- R&D expenses $48.9M (down from $70.0M); net loss $61.2M ($13.38/share) vs $93.1M ($23.08) in 2022.
- Phase 1a interim data for HSV drug ABI-5366 expected Q3 2024; Phase 1b data for HBV drug ABI-4334 by end of 2024.
- Entered long-term partnership with Gilead and appointed Anuj Gaggar as CMO.

## SEC filing metadata
- accession: 0000950170-24-038044
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000095017024038044/0000950170-24-038044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000095017024038044/asmb-20240328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-038044
- JSON: https://secwatch.observer/filing/0000950170-24-038044.json
- Plain text: https://secwatch.observer/filing/0000950170-24-038044.txt

## Key facts
- Earnings Releases
  ASSEMBLY BIOSCIENCES, INC. reported the quarter and year ended December 31, 2023 results: revenue $7.2 million, net income $61.2 million, EPS $13.38 per basic and diluted share.
  - Period: the quarter and year ended December 31, 2023
  - Revenue: $7.2 million
  - Net income: $61.2 million
  - EPS: $13.38 per basic and diluted share
  - Result: reported results
  source text: as of the year ended December 31, 2022. The company’s cash position is projected to fund operations into the second half of 2025. • Revenues from collaborative research were $7.2 million for the year ended December 31, 2023. There was no revenue recognized for the same period in 2022. Revenue for the year ended December 31, 2023, consists of $4.4 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1426800/000095017024038044/0000950170-24-038044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.